Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. Headquartered in San Diego, California, the company's commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Acadia primarily operates in the United States, targeting underserved patient populations with specialized neurological needs.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
1,071,505
957,797
726,437
517,235
Cost of Sales
88,998
81,841
41,638
10,166
Gross Profit
982,507
875,956
684,799
507,069
Selling, General & Administrative Expenses
548,894
488,428
406,559
369,090
Research & Development Expenses
328,802
303,249
351,619
361,575
Other Operating Expenses
—
(146,515)
—
—
Operating Profit
104,811
230,794
(73,379)
(223,596)
Interest and Investment Income
31,722
25,458
17,234
6,610
Non-Operating Income
2,371
1,823
5,109
3,542
Total Non-Operating Income
34,093
27,281
22,343
10,152
Income Before Provision for Income Taxes
138,904
258,075
(51,036)
(213,444)
Provision for Income Taxes
(252,096)
31,624
10,250
2,531
Consolidated Net Income
391,000
226,451
(61,286)
(215,975)
Net Income Attributable to Common Shareholders
391,000
226,451
(61,286)
(215,975)
Basic EPS
2.32
1.37
-0.37
-1.34
Diluted EPS
2.30
1.36
-0.37
-1.34
Basic Weighted Average Shares Outstanding
168,356
165,717
163,819
161,683
Diluted Weighted Average Shares Outstanding
169,919
166,362
163,819
161,683
Shares Outstanding
170,309
166,709
164,650
162,065
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
177,695
319,589
188,657
114,846
Short-Term Investments
641,991
436,404
250,208
301,977
Total Cash and Cash Equivalents
819,686
755,993
438,865
416,823
Accounts Receivable
121,457
98,739
98,267
62,195
Other Receivables
26,774
5,956
4,083
885
Total Trade Receivables
148,231
104,695
102,350
63,080
Inventories
34,670
21,949
35,819
6,636
Other Current Assets
59,526
55,681
39,091
21,398
Total Current Assets
1,062,113
938,318
616,125
507,937
Net Property, Plant & Equipment
54,865
50,786
56,467
61,594
Net Intangible Assets
108,893
119,782
65,490
—
Other Long-Term Assets
338,324
78,870
10,874
18,281
Total Assets
1,564,195
1,187,756
748,956
587,812
Accounts Payable
10,903
16,192
17,543
12,746
Accrued Expenses
266,211
378,678
236,711
112,884
Total Current Liabilities
277,114
394,870
254,254
125,630
Leases
40,554
42,037
47,800
52,695
Other Long-Term Liabilities
19,137
18,056
15,147
9,074
Total Long-Term Liabilities
59,691
60,093
62,947
61,769
Total Liabilities
336,805
454,963
317,201
187,399
Common Stock
16
16
16
16
Additional Paid-in Capital
3,039,315
2,936,871
2,862,552
2,770,923
Accumulated Other Comprehensive Income
1,445
292
24
(975)
Retained Earnings
(1,813,386)
(2,204,386)
(2,430,837)
(2,369,551)
Total Common Shareholders' Equity
1,227,390
732,793
431,755
400,413
Total Shareholders' Equity
1,227,390
732,793
431,755
400,413
Total Liabilities and Shareholders' Equity
1,564,195
1,187,756
748,956
587,812
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
391,000
226,451
(61,286)
(215,975)
Depreciation & Amortization
11,760
15,883
5,552
—
Share-Based Compensation Expense
52,135
67,049
66,421
68,201
Other Adjustments
(255,303)
(155,819)
(12,118)
(4,252)
Changes in Trade Receivables
(43,536)
(2,345)
(39,270)
2,264
Changes in Inventories
(18,197)
(49,550)
(28,808)
2,415
Changes in Accounts Payable
(5,289)
(1,351)
4,797
5,870
Changes in Accrued Expenses
(19,265)
71,061
93,170
24,306
Changes in Other Operating Activities
(3,469)
(13,660)
(11,756)
3,136
Cash from Operating Activities
109,836
157,719
16,702
(114,035)
Capital Expenditure
(4,690)
(523)
(50)
—
Proceeds from Sale of Property, Plant & Equipment
—
146,515
—
—
Purchases of Intangible Assets
(98,838)
—
(40,000)
—
Purchases of Investments
(692,565)
(505,095)
(369,985)
(363,174)
Proceeds from Sale of Investments
493,529
328,565
442,033
436,415
Cash from Investing Activities
(302,564)
(30,538)
31,998
73,241
Issuance of Common Shares
49,883
6,845
25,129
8,199
Net Issuance / (Repurchases) of Common Shares
49,883
6,845
25,129
8,199
Cash from Financing Activities
49,883
6,845
25,129
8,199
Effect of Exchange Rate Changes on Cash and Cash Equivalents
26
(94)
(18)
6
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash